JAB 21822

Phase 3Small molecule

AAllist Pharmaceuticals, Inc.

JAB 21822 is one of 175 small molecule programs targeting NSCLC. It is currently in Phase 3.

Indications

Total Trials

Active Trials

174

Competitors

Pipeline

Status by Indication[3][1]

Indication

NSCLCActive, not recruiting

KRAS P.G12CRecruiting

ChemotherapyActive, not recruiting

Non-Small Cell Lung CancerRecruiting

Pancreatic CancerRecruiting

Other Solid TumorsActive, not recruiting

NSCLCPreclinical

Active, not recruiting

KRAS P.G12CPreclinical

Recruiting

ChemotherapyPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Pancreatic CancerPhase 2

Recruiting

Other Solid TumorsPhase 2

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Albumin Paclitaxel

CChipscreen Biosciences, Ltd.

Phase 3

3 2

JAB 21822

AAllist Pharmaceuticals, Inc.

Phase 3

1 3

Remeron

OOrganon and Co

Preclinical

1 4

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 5

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

2 10

Pyrotinib Maleate

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Other Solid Tumors

NCT05194995

PreclinicalActive, not recruiting

NSCLC

NCT05009329

Q1 2027

PreclinicalRecruiting

KRAS P.G12C

NCT05288205

Q3 2027

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT05276726

Q4 2027

Phase 2Recruiting

Pancreatic Cancer

NCT06008288

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Recruiting·AAllist Pharmaceuticals, Inc.·Phase 2·NCT06008288·88 enrolled

Other Solid Tumors1 trial

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Active, not recruiting·AAllist Pharmaceuticals, Inc.·Phase 1/2·NCT05194995·48 enrolled

Drug Interactions1 trial

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

Completed·AAllist Pharmaceuticals, Inc.·Phase 1·NCT06162169·66 enrolled

Chemotherapy1 trial

JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

Active, not recruiting·JJian Li·Phase 1·NCT06838338·30 enrolled

KRAS P.G12C1 trial

A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Recruiting·AAllist Pharmaceuticals, Inc.·Preclinical·NCT05288205·240 enrolled

4 more indications

Advanced Non-squamous Non-small-cell Lung Cancer1 trial

An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Recruiting·AAllist Pharmaceuticals, Inc.·Phase 3·NCT06416410·392 enrolled

NSCLC1 trial

Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation

Active, not recruiting·AAllist Pharmaceuticals, Inc.·Preclinical·NCT05009329·315 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase Ib/II ,Single Arm, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With a KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Recruiting·AAllist Pharmaceuticals, Inc.·Preclinical·NCT05276726·104 enrolled

Unspecified1 trial

A Food Effect Study of JAB-21822 in Healthy Subjects

Completed·AAllist Pharmaceuticals, Inc.·Phase 1·NCT05875493·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for JAB 21822. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JAB 21822 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JAB 21822. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Allist Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAllist Pharmaceuticals, Inc.

JAB 21822

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Pancreatic Cancer1 trial

Other Solid Tumors1 trial

Drug Interactions1 trial

Chemotherapy1 trial

KRAS P.G12C1 trial

Advanced Non-squamous Non-small-cell Lung Cancer1 trial

NSCLC1 trial

Non-Small Cell Lung Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News